Stockscreener 앱 받기
20.46
1.21%
-0.23
전일 마감가:
$20.69
열려 있는:
$20.49
하루 거래량:
2.92M
Relative Volume:
1.17
시가총액:
$2.59B
수익:
$715.22M
순이익/손실:
$-250.10M
주가수익비율:
-10.08
EPS:
-2.03
순현금흐름:
$-205.58M
1주 성능:
-31.98%
1개월 성능:
-14.12%
6개월 성능:
+0.49%
1년 성능:
-28.43%
1일 변동 폭
$19.44
$20.65
1주일 범위
$19.25
$30.44
52주 변동 폭
$16.10
$35.72
아펠리스 Stock (APLS) Company Profile
명칭
Apellis Pharmaceuticals Inc
전화
617-977-5700
주소
100 FIFTH AVENUE, WALTHAM, KY
APLS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
APLS
Apellis Pharmaceuticals Inc
|
20.51 | 2.62B | 715.22M | -250.10M | -205.58M | -2.03 |
|
VRTX
Vertex Pharmaceuticals Inc
|
421.09 | 109.22B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
626.29 | 67.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
422.02 | 57.35B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
831.60 | 50.87B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
183.16 | 39.72B | 447.02M | -1.18B | -868.57M | -6.1812 |
아펠리스 Stock (APLS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-15 | 개시 | Wells Fargo | Overweight |
| 2025-09-26 | 다운그레이드 | Goldman | Neutral → Sell |
| 2025-05-09 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2025-05-09 | 다운그레이드 | Raymond James | Strong Buy → Outperform |
| 2025-04-29 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-12-17 | 다운그레이드 | Goldman | Buy → Neutral |
| 2024-11-21 | 개시 | Morgan Stanley | Equal-Weight |
| 2024-10-25 | 개시 | RBC Capital Mkts | Sector Perform |
| 2024-10-16 | 개시 | Scotiabank | Sector Outperform |
| 2024-10-16 | 개시 | William Blair | Outperform |
| 2024-05-31 | 개시 | Piper Sandler | Neutral |
| 2024-02-05 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-12-14 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2023-11-09 | 개시 | Goldman | Buy |
| 2023-11-02 | 개시 | Mizuho | Neutral |
| 2023-10-06 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2023-09-15 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2023-08-29 | 재확인 | Citigroup | Buy |
| 2023-08-03 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2023-08-01 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2023-01-03 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2022-11-10 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-07-19 | 개시 | H.C. Wainwright | Buy |
| 2022-06-17 | 재개 | Stifel | Buy |
| 2022-04-14 | 다운그레이드 | ROTH Capital | Neutral → Sell |
| 2021-12-08 | 개시 | Wells Fargo | Overweight |
| 2021-11-29 | 다운그레이드 | ROTH Capital | Buy → Neutral |
| 2021-09-10 | 재확인 | BMO Capital Markets | Outperform |
| 2021-09-10 | 재확인 | Credit Suisse | Neutral |
| 2021-09-10 | 재확인 | Needham | Buy |
| 2021-09-10 | 재확인 | Oppenheimer | Outperform |
| 2021-09-10 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2021-08-19 | 개시 | Jefferies | Buy |
| 2021-08-19 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2021-05-21 | 개시 | UBS | Buy |
| 2021-04-16 | 개시 | Goldman | Buy |
| 2020-11-19 | 개시 | Needham | Buy |
| 2020-09-01 | 개시 | Stifel | Buy |
| 2020-07-20 | 개시 | ROTH Capital | Buy |
| 2020-06-17 | 개시 | BTIG Research | Neutral |
| 2020-04-01 | 개시 | Raymond James | Strong Buy |
| 2020-03-31 | 개시 | BMO Capital Markets | Outperform |
| 2020-03-11 | 업그레이드 | Wedbush | Underperform → Neutral |
| 2020-01-07 | 개시 | SVB Leerink | Mkt Perform |
| 2019-12-19 | 개시 | BofA/Merrill | Buy |
| 2019-11-22 | 개시 | Wedbush | Underperform |
| 2019-11-05 | 개시 | Credit Suisse | Neutral |
| 2019-08-01 | 재확인 | Cantor Fitzgerald | Overweight |
| 2019-07-12 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2019-03-29 | 개시 | Robert W. Baird | Outperform |
| 2019-01-23 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2018-07-30 | 업그레이드 | B. Riley FBR | Neutral → Buy |
| 2018-05-24 | 개시 | Cantor Fitzgerald | Overweight |
| 2018-04-12 | 다운그레이드 | B. Riley FBR, Inc. | Buy → Neutral |
| 2018-02-08 | 개시 | B. Riley FBR, Inc. | Buy |
모두보기
아펠리스 주식(APLS)의 최신 뉴스
21,011 Shares in Apellis Pharmaceuticals, Inc. $APLS Bought by Corton Capital Inc. - MarketBeat
Can Apellis Pharmaceuticals Inc. stock resist sector downturnsWeekly Trend Report & Safe Capital Growth Stock Tips - newser.com
How moving averages guide Apellis Pharmaceuticals Inc. trading2025 Stock Rankings & Real-Time Chart Pattern Alerts - newser.com
Will Apellis Pharmaceuticals Inc. see short term momentumTrade Performance Summary & Target Return Focused Stock Picks - newser.com
Apellis Pharmaceuticals (APLS): Mizuho Adjusts Price Target and Rating Update | APLS Stock News - GuruFocus
Risk vs reward if holding onto Apellis Pharmaceuticals Inc.Portfolio Value Report & Safe Swing Trade Setups - newser.com
Using AI based signals to follow Apellis Pharmaceuticals Inc.July 2025 Decliners & Smart Money Movement Alerts - newser.com
Real time scanner hits for Apellis Pharmaceuticals Inc. explainedJuly 2025 Market Mood & Safe Entry Trade Reports - newser.com
Is Apellis Pharmaceuticals Inc. stock attractive for income investorsWeekly Market Summary & Expert Approved Momentum Ideas - newser.com
Why Apellis Pharmaceuticals Inc. (1JK) stock could rally stronglyMarket Movement Recap & AI Driven Stock Price Forecasts - newser.com
Will breakout in Apellis Pharmaceuticals Inc. lead to full recoveryJuly 2025 Big Picture & AI Based Buy/Sell Signal Reports - newser.com
Will a bounce in Apellis Pharmaceuticals Inc. offer an exitWeekly Market Summary & Safe Capital Allocation Plans - newser.com
How to build a dashboard for Apellis Pharmaceuticals Inc. stockTrade Performance Summary & Smart Swing Trading Techniques - newser.com
How interest rate cuts could boost Apellis Pharmaceuticals Inc. stock2025 Volatility Report & Safe Capital Growth Stock Tips - newser.com
Why Apellis Pharmaceuticals Inc. stock is rated strong buy2025 Price Momentum & AI Enhanced Trading Signals - newser.com
Will Apellis Pharmaceuticals Inc. (1JK) stock rise with strong economyWeekly Investment Recap & Community Verified Trade Alerts - newser.com
Will Apellis Pharmaceuticals Inc. stock maintain dividend yieldEarnings Overview Report & Daily Stock Trend Reports - newser.com
Can Apellis Pharmaceuticals Inc. (1JK) stock survive global slowdownEarnings Performance Report & Verified Short-Term Plans - newser.com
Does Apellis Pharmaceuticals Inc. (1JK) stock trade below intrinsic valueEarnings Recap Summary & Weekly High Return Stock Opportunities - newser.com
Regression analysis insights on Apellis Pharmaceuticals Inc. performanceQuarterly Profit Review & Daily Growth Stock Investment Tips - newser.com
Apellis Stock Down Despite Q3 Earnings and Revenues Beat Estimates - MSN
Apellis Pharmaceuticals Hits Day Low of $20.66 Amid Price Pressure - Markets Mojo
Brighton Jones LLC Buys Shares of 16,539 Apellis Pharmaceuticals, Inc. $APLS - MarketBeat
Apellis Pharmaceuticals Inc. recovery potential after sell off2025 Market WrapUp & Verified Momentum Stock Watchlist - newser.com
Apellis Pharmaceuticals Inc. stock prediction for this weekWeekly Trend Recap & Smart Money Movement Tracker - newser.com
Why retail investors favor Apellis Pharmaceuticals Inc. stockJuly 2025 Selloffs & Weekly High Return Stock Forecasts - newser.com
Citigroup Issues Pessimistic Forecast for Apellis Pharmaceuticals (NASDAQ:APLS) Stock Price - MarketBeat
Apellis Pharmaceuticals (NASDAQ:APLS) Price Target Lowered to $45.00 at TD Cowen - MarketBeat
Apellis Pharmaceuticals (NASDAQ:APLS) Price Target Cut to $45.00 by Analysts at HC Wainwright - MarketBeat
Robert W. Baird Issues Positive Forecast for Apellis Pharmaceuticals (NASDAQ:APLS) Stock Price - MarketBeat
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Q3 2025 Earnings Call Transcript - Insider Monkey
How sentiment analysis helps forecast Apellis Pharmaceuticals Inc.July 2025 Movers & Weekly High Return Opportunities - newser.com
Jennison Associates LLC Raises Holdings in Apellis Pharmaceuticals, Inc. $APLS - MarketBeat
Y Intercept Hong Kong Ltd Has $2.84 Million Stock Position in Apellis Pharmaceuticals, Inc. $APLS - MarketBeat
Apellis Pharmaceuticals, Inc. $APLS Shares Sold by AlphaQuest LLC - MarketBeat
How Apellis Pharmaceuticals Inc. stock performs in weak economyJuly 2025 Breakouts & Verified Chart Pattern Signals - newser.com
Apellis Pharmaceuticals’ Earnings Call Highlights FDA Approval and Market Challenges - TipRanks
APLS: Citigroup Lowers Price Target Amidst Maintained Buy Rating - GuruFocus
Apellis Pharmaceuticals (NASDAQ:APLS) Shares Gap DownTime to Sell? - MarketBeat
Apellis Pharmaceuticals Inc Stock Analysis and ForecastDividend Cut Warnings & Free Wealth Planning Blueprints - earlytimes.in
APLS Analyst Rating Update: TD Cowen Adjusts Price Target | APLS Stock News - GuruFocus
Apellis Pharmaceuticals (NASDAQ:APLS) Releases Quarterly Earnings Results, Beats Estimates By $0.64 EPS - MarketBeat
Apellis Pharmaceuticals, Inc. 2025 Q3ResultsEarnings Call Presentation (NASDAQ:APLS) 2025-10-31 - Seeking Alpha
Apellis Pharmaceuticals (APLS): Forecast 13% Annual Revenue Growth, Shares Trade at Deep Discount Heading Into Earnings - Yahoo Finance
APLS Stock: Baird Raises Price Target to $52, Maintains Outperfo - GuruFocus
APLS: HC Wainwright & Co. Lowers Price Target, Maintains 'Buy' R - GuruFocus
APLS: HC Wainwright & Co. Lowers Price Target, Maintains 'Buy' Rating | APLS Stock News - GuruFocus
아펠리스 (APLS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
아펠리스 주식 (APLS) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Sullivan Timothy Eugene | Chief Financial Officer |
Oct 21 '25 |
Sale |
28.03 |
10,000 |
280,300 |
110,936 |
1.18%
0.56%
자본화:
|
볼륨(24시간):